Home › Research › Biomarkers
Primary motor cortex alterations in Alzheimer disease: A study in the 3xTg-AD model
Orta-Salazar E, Feria-Velasco AI, Díaz-Cintra S.. Neurologia, 2017-04-19
Topic: Amyloid, tau and blood-test diagnosis
Introduction In humans and animal models, Alzheimer disease (AD) is characterised by accumulation of amyloid-β peptide (Aβ) and hyperphosphorylated tau protein, neuronal degeneration, and astrocytic gliosis, especially in vulnerable brain regions (hippocampus and cortex). These alterations are associated with cognitive impairment (loss of memory) and non-cognitive impairment (motor impairment). The purpose of this study was to identify cell changes (neurons and glial cells) and aggregation of Aβ and hyperphosphorylated tau protein in the primary motor cortex (M1) in 3xTg-AD mouse models at an intermediate stage of AD. Methods We used female 3xTg-AD mice aged 11 months and compared them to non-transgenic mice of the same age. In both groups, we assessed motor performance (open field test) and neuronal damage in M1 using specific markers: BAM10 (extracellular Aβ aggregates), tau 499 (hyperphosphorylated tau protein), GFAP (astrocytes), and Klüver-Barrera staining (neurons). Results Female 3xTg-AD mice in intermediate stages of the disease displayed motor and cellular alterations associated with Aβ and hyperphosphorylated tau protein deposition in M1. Conclusions Patients with AD display signs and symptoms of functional impairment from early stages. According to our results, M1 cell damage in intermediate-stage AD affects motor function, which is linked to progression of the disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Orta-Salazar, E., Feria-Velasco, A. I., & Díaz-Cintra, S. (2019). Primary motor cortex alterations in Alzheimer disease: A study in the 3xTg-AD model. Neurologia. https://doi.org/10.1016/j.nrl.2017.02.016
Vancouver
Orta-Salazar E, Feria-Velasco AI, Díaz-Cintra S. Primary motor cortex alterations in Alzheimer disease: A study in the 3xTg-AD model. Neurologia. 2019. doi:10.1016/j.nrl.2017.02.016. PMID: 28433262.
BibTeX
@article{ortasalazar2019-28433262,
author = {Orta-Salazar, E. and Feria-Velasco, A. I. and Díaz-Cintra, S.},
title = {{Primary motor cortex alterations in Alzheimer disease: A study in the 3xTg-AD model}},
journal = {Neurologia},
year = {2019},
doi = {10.1016/j.nrl.2017.02.016},
pmid = {28433262},
url = {https://doi.org/10.1016/j.nrl.2017.02.016}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- These alterations are associated with cognitive impairment (loss of memory) and non-cognitive impairment (motor impairment).
- Results Female 3xTg-AD mice in intermediate stages of the disease displayed motor and cellular alterations associated with Aβ and hyperphosphorylated tau protein deposition in M1.
- According to our results, M1 cell damage in intermediate-stage AD affects motor function, which is linked to progression of the disease.
Why it matters
In 11-month-old female 3xTg-AD mice, motor and cellular changes in the primary motor cortex were linked to amyloid-beta and hyperphosphorylated tau deposition. This is an animal-model study and does not show any treatment, cure or prevention for people.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 22 of the 64 points we could judge it on, which is 34 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurologia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “3xtg”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (OpenAlex dates this DOI to 2017, the record says 2019; OpenAlex values not used) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28433262) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 64 points we could judge it on is 34 out of 100. |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.